RORA and metabolic dysfunction-associated steatohepatitis: RORα and its inverse processes, including REV-ERB (reverse orientation the c-erbA-1 gene) nuclear receptors, may be targeted using synthetic ligands for treating several diseases [27], including atherosclerosis [38,39], nonalcoholic steatohepatitis (NASH) [40], and autism [41].